Abstract
Purpose: We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29) when implemented with Korean patients by conducting a multicenter, longitudinal study in three Korean hospitals. Methods: A total of 226 patients who scheduled to receive the HDC followed by hematopoietic stem cell transplantation (HSCT) were enrolled. The patients were asked to complete three questionnaires [the EORTC Core Questionnaire (QLQ-C30), QLQ-HDC29, and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation] at four points in time: before HSCT and 100, 180, and 365 days after HSCT. Standard validity and reliability analyses were performed. Results: Internal consistency of the QLQ-HDC29 was generally acceptable, as tested by Cronbach’s α, except for the scales body image and the inpatient issues. Cronbach’s α values for the Korean version of the QLQ-HDC29 were almost in accordance with results of the original version, except for the scales body image (lower to the original QLQ-HDC29, α = 0.73) and impact on family (higher to the original QLQ-HDC29, α = 0.52). Known-group comparison analyses showed significantly higher symptom burdens in patients with poor performance status or graft versus host disease (similar to the original QLQ-HDC29). The QLQ-HDC29 indicated good convergent and discriminant validity and showed responsiveness to changes in line with a clinical course over time after HSCT. Conclusions: The QLQ-HDC29 is generally reliable and adequate to assess QoL in Korean patients undergoing HDC followed by HSCT.
| Original language | English |
|---|---|
| Pages (from-to) | 881-890 |
| Number of pages | 10 |
| Journal | Quality of Life Research |
| Volume | 25 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2016 Apr 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Public Health, Environmental and Occupational Health
Cite this
}
Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29). / Kim, Kyung Im; Kim, Jae Hyun; Ji, Eun Hee; Jang, Jun Ho; Kim, Jinseok; Kwon, Ji Hyun; Kim, Inho; Park, Seonyang; Velikova, Galina; Yoon, Sung Soo; Oh, Jung Mi.
In: Quality of Life Research, Vol. 25, No. 4, 01.04.2016, p. 881-890.Research output: Contribution to journal › Article
TY - JOUR
T1 - Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29)
AU - Kim, Kyung Im
AU - Kim, Jae Hyun
AU - Ji, Eun Hee
AU - Jang, Jun Ho
AU - Kim, Jinseok
AU - Kwon, Ji Hyun
AU - Kim, Inho
AU - Park, Seonyang
AU - Velikova, Galina
AU - Yoon, Sung Soo
AU - Oh, Jung Mi
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Purpose: We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29) when implemented with Korean patients by conducting a multicenter, longitudinal study in three Korean hospitals. Methods: A total of 226 patients who scheduled to receive the HDC followed by hematopoietic stem cell transplantation (HSCT) were enrolled. The patients were asked to complete three questionnaires [the EORTC Core Questionnaire (QLQ-C30), QLQ-HDC29, and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation] at four points in time: before HSCT and 100, 180, and 365 days after HSCT. Standard validity and reliability analyses were performed. Results: Internal consistency of the QLQ-HDC29 was generally acceptable, as tested by Cronbach’s α, except for the scales body image and the inpatient issues. Cronbach’s α values for the Korean version of the QLQ-HDC29 were almost in accordance with results of the original version, except for the scales body image (lower to the original QLQ-HDC29, α = 0.73) and impact on family (higher to the original QLQ-HDC29, α = 0.52). Known-group comparison analyses showed significantly higher symptom burdens in patients with poor performance status or graft versus host disease (similar to the original QLQ-HDC29). The QLQ-HDC29 indicated good convergent and discriminant validity and showed responsiveness to changes in line with a clinical course over time after HSCT. Conclusions: The QLQ-HDC29 is generally reliable and adequate to assess QoL in Korean patients undergoing HDC followed by HSCT.
AB - Purpose: We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29) when implemented with Korean patients by conducting a multicenter, longitudinal study in three Korean hospitals. Methods: A total of 226 patients who scheduled to receive the HDC followed by hematopoietic stem cell transplantation (HSCT) were enrolled. The patients were asked to complete three questionnaires [the EORTC Core Questionnaire (QLQ-C30), QLQ-HDC29, and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation] at four points in time: before HSCT and 100, 180, and 365 days after HSCT. Standard validity and reliability analyses were performed. Results: Internal consistency of the QLQ-HDC29 was generally acceptable, as tested by Cronbach’s α, except for the scales body image and the inpatient issues. Cronbach’s α values for the Korean version of the QLQ-HDC29 were almost in accordance with results of the original version, except for the scales body image (lower to the original QLQ-HDC29, α = 0.73) and impact on family (higher to the original QLQ-HDC29, α = 0.52). Known-group comparison analyses showed significantly higher symptom burdens in patients with poor performance status or graft versus host disease (similar to the original QLQ-HDC29). The QLQ-HDC29 indicated good convergent and discriminant validity and showed responsiveness to changes in line with a clinical course over time after HSCT. Conclusions: The QLQ-HDC29 is generally reliable and adequate to assess QoL in Korean patients undergoing HDC followed by HSCT.
UR - http://www.scopus.com/inward/record.url?scp=84940845614&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940845614&partnerID=8YFLogxK
U2 - 10.1007/s11136-015-1121-5
DO - 10.1007/s11136-015-1121-5
M3 - Article
VL - 25
SP - 881
EP - 890
JO - Quality of Life Research
JF - Quality of Life Research
SN - 0962-9343
IS - 4
ER -